Opportunities and challenges in bi-, multi-specific, and antibody-fusion therapies for cancer
28 Apr 2026
Bi/Multispecifics
- Target & Pathway Selection – What criteria should guide the choice of targets/biologies/pathways to maximize tumor specificity while minimizing toxicity?
- On-Target / Off-Tumor Toxicity – How can we best balance potency with safety when engaging multiple targets, cell types or pathways simultaneously?
- Synergy vs. Additivity – What strategies and preclinical models can reliably demonstrate true synergy rather than additive effects?
- Immunogenicity Risks – How can we anticipate, monitor, and mitigate immune responses against engineered or non-natural domains?
